Functional ovarian hyperandrogenism and polycystic ovary syndrome in adolescence;Hiperandrogenismo ovárico funcional y síndrome del ovario poliquístico en la adolescencia

Endocrinologia y Nutricion

Volumn 53, Issue SUPPL. 1, 2006, Pages 34-40

  Ibanez Toda L ^a   Potau Vilalta, N ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL MATERNO INFANTIL VALL D HEBRON   (Spain)

Author keywords

Insulin resistance; Metabolic syndrome; Metformin; Polycystic ovary syndrome (PCOS)

Indexed keywords

ADIPONECTIN; FLUTAMIDE; INTERLEUKIN 6; LIPID; METFORMIN; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; ECHOGRAPHY; HIGH RISK PATIENT; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN RESISTANCE; LOW BIRTH WEIGHT; METABOLIC DISORDER; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; OVULATION; PRECOCIOUS PUBERTY; PUBERTY; REVIEW; RISK FACTOR;

EID: 34547696886     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/s1575-0922(06)71167-6     Document Type: Review

References (68)

1. Asunción M, Calvo RM, San Millán JL, Sancho J, Ávila S, Escobar-Morreale H. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85:2434-8.
2. Ibáñez L, Potau N, Zampolli M, Prat N, Gussinyé M, Saenger P, et al. Source localization of androgen excess in adolescent girls. J Clin Endocrinol Metab. 1994;79:1778-84.
3. Baumann EE, Rosenfield RL. Polycystic ovary syndrome in adolescence. The Endocrinologist. 2002;12:333-48.
4. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41-7.
5. Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab. 2006;91:781-5.
6. Franks S. Diagnosis of polycystic ovary syndrome: in defence of the Rotterdam criteria. J Clin Endocrinol Metab. 2006;91:786-9.
7. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18:774-800.
8. Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod. 2001;16:1255-60.
9. Ducluzeau PH, Cousin P, Malvoisin E, Bornet H, Vidal H, Laville M, et al. Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:3626-31.
10. Ibáñez L, Ong K, Ferrer A, Amin R, Dunger D, de Zegher F. Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in non-obese adolescents and young women with ovarian hyperandrogenism. J Clin Endocrinol Metab. 2003;88:2600-6.
11. Ibáñez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab. 2004;89:1592-7.
12. Orio F Jr, Palomba S, Cascella T, Di Biase S, Manguso F, Tauchmanova L, et al. The increase of leukocytes as a new putative marker of low grade chronic inflammation and early cardiovascular risk in the polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:2-5.
13. Ibáñez L, Valls C, de Zegher F. Discontinuous low-dose flutamide-metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinemic hyperandrogenism: normalizing effects on C-reactive protein, tumor necrosis factor-α and the neutrophil/lymphocyte ratio. Hum Reprod. 2006;21:451-6.
14. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab. 2004;89:2160-5.
15. Després JP, Lamarche B, Mauriège P, Cantin B, Dagenais G, Moorjani S, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-7.
16. Rexrode KM, Pradhan A, Manson JE, Buring JE, Ridker PM. Relationship total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol. 2003;13:674-82.
17. Tsai JC, Sheu SH, Chiu HC, Chung FM, Chang DM, Chen MP, et al. Association of peripheral total and differential leukocyte counts with metabolic syndrome and risk of ischemic cardiovascular diseases in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2006 [Epub ahead of print].
18. Essah PA, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. J Endocrinol Invest. 2006;29:270-80.
19. Ibáñez L, Di Martino-Nardi J, Potau N, Saenger P. Premature adrenarche -normal variant or forerunner of adult disease? Endocr Rev. 2000;21:671-96.
20. Ibáñez L, Potau N, Francois I, de Zegher F. Precocious pubarche, hyperinsulinism and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab. 1998;83:3558-662.
21. Ibáñez L, Valls C, Potau N, Marcos MV, de Zegher F. Polycystic ovary syndrome after precocious pubarche: ontogeny of the low-birthweight effect. Clin Endocrinol. 2001;55:667-72.
22. Ibáñez L, Valls C, Miró E, Marcos MV, de Zegher F. Early menarche and subclinical ovarian hyperandrogenism in girls with reduced adult height after low birthweight. J Pediatr Endocrinol Metab. 2002;15:431-3.
23. Ibáñez L, Potau N, Chacón P, Pascual C, Carrascosa A. Hyperinsulinemia, dyslipaemia and cardiovascular risk in girls with a history of premature pubarche. Diabetologia. 1998;41:1057-63.
24. Ibáñez L, Potau N, de Zegher F. Precocious pubarche, dyslipidemia and low IGFBP-1 in girls: relation to reduced prenatal growth. Pediatr Res. 1999;46:320-2.
25. Ibáñez L, Ong K, de Zegher F, Marcos MV, Del Río L, Dunger D. Fat distribution in non-obese girls with and without precocious pubarche: central adiposity related to insulinemia and androgenemia from pre-puberty to post-menarche. Clin Endocrinol. 2003;58:372-9.
26. Ibáñez L, Valls C, Marcos MV, Ong K, Dunger D, de Zegher F. Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin. J Clin Endocrinol Metab. 2004;89:4331-7.
27. Ibáñez L, Potau N, Marcos MV, de Zegher F. Adrenal hyperandrogenism in adolescent girls with a history of low birthweight and precocious pubarche. Clin Endocrinol. 2000;53:523-7.
28. Ibáñez L, de Zegher F, Potau N. Anovulation after precocious pubarche: early markers and time course in adolescence. J Clin Endocrinol Metab. 1999;84:2691-5.
29. Ibáñez L, Potau N, Ferrer A, Rodríguez-Hierro F, Marcos MV, de Zegher F. Reduced ovulation rate in adolescent girls born small for gestational age. J Clin Endocrinol Metab. 2002;87:3391-3.
30. Ibáñez L, Potau N, Ferrer A, Rodríguez-Hierro F, Marcos MV, de Zegher F. Anovulation in eumenorheic, non-obese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia and subclinical hyperandrogenism. J Clin Endocrinol Metab. 2002;87:5702-5.
31. De Leo V, Lanzetta D, D'Antona D, La Marca A, Morgante G. Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83:99-102.
32. Ibáñez L, Potau N, Marcos MV, de Zegher F. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia and hyperinsulinism in non-obese, adolescent girls: effect of flutamide. J Clin Endocrinol Metab. 2000;85:3251-5.
33. Franks S, McCarthy MI, Hardy K. Development of polycystic ovary syndrome: involvement of genetic and environmental factors. Int J Androl. 2006;29:278-85.
34. Xita N, Tsatsoulis A. Fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies. J Clin Endocrinol Metab. 2006;91:1660-6.
35. Kristiansen SB, Endoh A, Casson PR, Buster JE, Hornsby PJ. Induction of steroidogenic enzyme genes by insulin and IGF-I in cultured adult human adrenocortical cells. Steroids. 1997;62:258-65.
36. Suikkari AM, Koivisto VA, Rutanen EM, Yki-Järvinen H, Karonen SL, Seppäla M. Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J Clin Endocrinol Metab. 1988;66:266-72.
37. Avvad CK, Holeuwerger R, Silva VC, Bordallo MA, Breutenbach MM. Menstrual irregularity in the first postmenarchal years: an early clinical sign of polycystic ovary syndrome in adolescence. Gynecol Endocrinol. 2001;15:170-7.
38. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440-7.
39. Kumar A, Woods KS, Bartolucci AA, Azziz R. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2005;62:644-9.
40. Kent SC, Legro RS. Polycystic ovary syndrome in adolescents. Adolesc Med. 2002;13:73-88.
41. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83:2694-8.
42. Matthews DR, Hosker JP, Rudenski AS, Aylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412-9.
43. Duncan MH, Singh BM, Wise PH, Carter G, Alaghband-Zadeh G. A simple measure of insulin resistance. Lancet. 1995;346:120-1.
44. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402-10.
45. Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:4649-54.
46. Reyss AC, Proust-Richard C, Catteau-Jonard S, Dewailly D. Rotterdam consensus in adolescent girls: which investigations and how to interpret them to make the diagnosis of PCOS? Gynecol Obstet Fertil. 2006;34:341-6.
47. Milchelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated and biochemical features in young women. Clin Endocrinol (Oxf). 1999;51:779-86.
48. Yao LQ, Kuang JQ, Feng YJ, Li L, Xu CJ. Characterization of unilateral polycystic ovary compared with polycystic ovary syndrome. Fertil Steril. 2006;85:805-8.
49. Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Nestler JE. Controversies in endocrinology. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab. 2003;88:1927-32.
50. De Leo V, La Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev. 2003;24:633-67.
51. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17α activity and serum androgens. J Clin Endocrinol Metab. 1997;82:4075-9.
52. Ibáñez L, Valls C, Potau N, Marcos MV, de Zegher F. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab. 2000;85:3526-30.
53. Ibáñez L, Valls C, Ferrer A, Marcos MV, Rodríguez- Hierro F, de Zegher F. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab. 2001;86:3595-8.
54. Stith BJ, Woronoff K, Wiernsperger N. Stimulation of the intracellular portion of the human insulin receptor by the antidiabetic drug metformin. Biochem Pharmacol. 1998;55:533-6.
55. Mansfield R, Galea R, Brincat M, Hole D, Mason H. Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril. 2003;79:956-62.
56. Ibáñez L, Valls C, Ferrer A, Ong K, Dunger D, de Zegher F. Additive effects of insulin-sensitizing and antiandrogen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia and anovulation J Clin Endocrinol Metab. 2002;87:2870-4.
57. Gambineri A, Pelusi C, Genghini S, Morselli-Labate AM, Cacciari M, Pagotto U, et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol. 2004;60:241-9.
58. Ibáñez L, Jaramillo AM, Ferrer A, de Zegher F. High neutrophil count in girls and women with hyperinsulinemic hyperandrogenism: normalization with metformin and flutamide overcomes aggravation by oral contraception. Hum Reprod. 2005;20:2457-62.
59. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaterani H, et al. Androgens decrease plasma adiponectin, and insulin-sensitizing adipocyte-derived protein. Diabetes. 2002;51:2734-41.
60. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl-estradiol-cyproterone-acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab. 2003;88:148-56.
61. Ibáñez L, de Zegher F. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Human Reproduction Update. 2006;12:243-52.
62. Ibáñez L, Valls C, Cabré S, de Zegher F. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and anti-atherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide. J Clin Endocrinol Metab. 2004;89:4716-20.
63. Ibáñez L, de Zegher F. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and anti-atherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at start and after more than one year of therapy. J Clin Endocrinol Metab. 2005;90:39-43.
64. Nestler JE. Should patients with polycystic ovary syndrome be treated with metformin? An enthusiastic endorsement. Hum Reprod. 2002;17:1950-3.
65. Ibáñez L, Ferrer A, Ong K, Amin R, Dunger D, de Zegher F. Insulin sensitization early post-menarche prevents progression from precocious pubarche to polycystic ovary syndrome. J Pediatr. 2004;144:23-9.
66. Ibáñez L, Jiménez R, de Zegher F. Early puberty-menarche after precocious pubarche: relation to prenatal growth. Pediatrics. 2006;117:117-21.
67. Ibáñez L, Ong K, Valls C, Marcos MV, Dunger DB, de Zegher F. Metformin treatment to prevent early puberty in girls with precocious pubarche. J Clin Endocrinol Metab. 2006 [Epub ahead of print].
68. Ibáñez L, Jaramillo A, Ferrer A, de Zegher F. Absence of hepatotoxicity after long-term, low-dose flutamide n hyperandrogenic girls and young women. Hum Reprod. 2005;20:1833-6.